Type your tag names separated by a space and hit enter

Galactomannan in the diagnosis of invasive aspergillosis in immunocompromized patients

Galactomannan in the diagnosis of invasive aspergillosis in immunocompromized patients is a topic covered in the Evidence-Based Medicine Guidelines.

To view the entire topic, please sign in or purchase a subscription.

Evidence Central is an integrated web and mobile solution that helps clinicians quickly answer etiology, diagnosis, treatment, and prognosis questions using the latest evidence-based research. Explore these free sample topics:

20 mcg versus >20 mcg estrogen combined oral contraceptives for contraception

"Snowball fingers" - Image

Botulinum toxin for the treatment of strabismus: Cochrane systematic review

ACC/AHA: Fewer patients require prophylaxis for endocarditis

Citation

"Galactomannan in the Diagnosis of Invasive Aspergillosis in Immunocompromized Patients." Evidence-Based Medicine Guidelines, Duodecim Medical Publications Limited, 2019. Evidence Central, evidence.unboundmedicine.com/evidence/view/EBMG/452047/all/Galactomannan_in_the_diagnosis_of_invasive_aspergillosis_in_immunocompromized_patients.

Galactomannan in the diagnosis of invasive aspergillosis in immunocompromized patients. Evidence-Based Medicine Guidelines. Duodecim Medical Publications Limited; 2019. https://evidence.unboundmedicine.com/evidence/view/EBMG/452047/all/Galactomannan_in_the_diagnosis_of_invasive_aspergillosis_in_immunocompromized_patients. Accessed February 21, 2019.

Galactomannan in the diagnosis of invasive aspergillosis in immunocompromized patients. (2019). In Evidence-Based Medicine Guidelines. Available from https://evidence.unboundmedicine.com/evidence/view/EBMG/452047/all/Galactomannan_in_the_diagnosis_of_invasive_aspergillosis_in_immunocompromized_patients

Galactomannan in the Diagnosis of Invasive Aspergillosis in Immunocompromized Patients [Internet]. In: Evidence-Based Medicine Guidelines. Duodecim Medical Publications Limited; 2019. [cited 2019 February 21]. Available from: https://evidence.unboundmedicine.com/evidence/view/EBMG/452047/all/Galactomannan_in_the_diagnosis_of_invasive_aspergillosis_in_immunocompromized_patients

* When formatting your citation, note that all book, journal, and database titles should be italicized* Article titles in AMA citation format should be in sentence-case

TY - ELEC T1 - Galactomannan in the diagnosis of invasive aspergillosis in immunocompromized patients ID - 452047 BT - Evidence-Based Medicine Guidelines UR - https://evidence.unboundmedicine.com/evidence/view/EBMG/452047/all/Galactomannan_in_the_diagnosis_of_invasive_aspergillosis_in_immunocompromized_patients PB - Duodecim Medical Publications Limited DB - Evidence Central DP - Unbound Medicine ER -